Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Label, Single Arm, Phase II Trial-Reference-Cited by-同舟云学术

Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Label, Single Arm, Phase II Trial

Published:2015-03 Issue:3 Volume:15 Page:152-158
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Oki Yasuhiro,Ewer Michael S.,Lenihan Daniel J.,Fisch Michael J.,Hagemeister Fredrick B.,Fanale Michelle,Romaguera Jorge,Pro Barbara,Fowler Nathan,Younes Anas,Astrow Alan B.,Huang Xuelin,Kwak Larry W.,Samaniego Felipe,McLaughlin Peter,Neelapu Sattva S.,Wang Michael,Fayad Luis E.,Durand Jean-Bernard,Alma Rodriguez M.

Funder

National Institutes of Health (NIH) Cancer Center

NIH Public Health Service

Ortho Biotech

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference23 articles.

1. Treatment strategies for aggressive lymphomas: what works?;Wilson;Hematology Am Soc Hematol Educ Prog,2013

2. Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction;Ewer;J Clin Oncol,2010

3. Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity;Lotrionte;Am J Cardiol,2013